AXID CAPSULE

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

NIZATIDINE

Beschikbaar vanaf:

PENDOPHARM DIVISION OF PHARMASCIENCE INC

ATC-code:

A02BA04

INN (Algemene Internationale Benaming):

NIZATIDINE

Dosering:

300MG

farmaceutische vorm:

CAPSULE

Samenstelling:

NIZATIDINE 300MG

Toedieningsweg:

ORAL

Eenheden in pakket:

100

Prescription-type:

Prescription

Therapeutisch gebied:

HISTAMINE H2-ANTAGONISTS

Product samenvatting:

Active ingredient group (AIG) number: 0120317002; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2002-02-04

Productkenmerken

_ _
_AXID (nizatidine) _
_Page 1 of 27_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AXID®
Nizatidine Capsules
Capsules 150 mg, 300 mg, Oral
USP
Histamine H
2
Receptor Antagonist
PENDOPHARM, Division of Pharmascience Inc.
6111 Royalmount Avenue, Suite 100
Montréal, QC, Canada
H4P 2T4
Date of Revision:
July 20, 2021
Submission Control Number: 247715
® Registered trademark of Pharmascience Inc.
_ _
_ _
_AXID (nizatidine) _
_Page 2 of 27_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
4
DOSAGE AND
ADMINISTRATION...................................................................................4
4.2
Recommended Dose and Dosage
Adjustment.......................................................4
4.4
Administration.....................................................................................................5
4.5
Missed Dose
........................................................................................................5
5
OVERDOSAGE
...............................................................................................................5
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
...................................6
7
WARNINGS AND PRECAUTIONS
...................................